The Liver Meeting
55th Annual Meeting of the American Association for the Study of
Liver Diseases

 

October 29 - November 2
Boston, Massachusetts
John B. Hynes Convention Center

Welcome to the HBV Advocate’s AASLD Conference coverage.  In an effort to best serve our readership, we will post all the important and interesting abstracts about HBV from the conference.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HBV related abstracts posted to www.aasld.org that we have not been able to report on or update.  

To locate specific abstracts on this page, click on “Edit” at the top of  your browser (Microsoft Internet Explorer) and then on Find (on this page).  In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.

Please click here to view our fact sheet on reading and understanding an abstract.

Thank You,

Alan Franciscus
Editor-in-Chief

Hepatitis B

HBV Antiviral Treatment

Lamivudine

§       EFFECT OF LAMIVUDINE THERAPY ON THE SERUM COVALENTLY CLOSED CIRCULAR DNA OF CHRONIC HEPATITIS B INFECTION (updated 11/03/2004)

§       LAMIVUDINE TREATMENT FOR ACUTE SEVERE HEPATITIS B (updated 11/03/2004)

§       THE LONG-TERM OUTCOME OF HBeAG-NEGATIVE PATIENTS WITH CIRRHOSIS TREATED WITH LAMIVUDINE MONOTHERAPY: A 5-YEAR PROSPECTIVE COHORT STUDY (updated 11/03/2004)

§       DYNAMICS OF HBV-DNA AND INFECTED HEPATOCYTES DESCRIBED BY A NEW BIO-MATHEMATICAL MODEL IN CHRONIC HEPATITIS B PATIENTS TREATED WITH LAMIVUDINE AND IN PATIENTS WITH YMDD MUTANTS TREATED WITH ADEFOVIR (updated 11/03/2004)

Adefovir

§       ONE YEAR RESULTS FROM A MULTI-CENTRE, DOUBLE-BLIND, PLACEBO (PLA)-CONTROLLED 5 YEAR STUDY OF ADEFOVIR DIPIVOXIL (ADV) IN CHINESE PATIENTS WITH HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) (updated 11/01/2004)

§       DIFFERENT PROFILES OF RESPONSE TO ADEFOVIR DIPIVOXIL AND FACTORS THAT MAY INFLUENCE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/03/2004)

§       ANALYSIS OF HBV POLYMERASE POLYMORPHISMS AND VIROLOGICAL RESPONSE TO ADEFOVIR DIPIVOXIL (ADV) IN CHRONIC HEPATITIS B (CHB) PATIENTS (updated 11/03/2004)

§       LONG TERM EFFICACY AND SAFETY OF ADEFOVIR DIPIVOXIL (ADV) 10 MG IN HBEAG+ CHRONIC HEPATITIS B (CHB) PATIENTS: INCREASING SEROLOGIC, VIROLOGIC AND BIOCHEMICAL RESPONSE OVER TIME (updated 11/03/2004)

§       RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ADEFOVIR DIPIVOXIL (ADV) PLUS EMTRICITABINE (FTC) COMBINATION THERAPY VERSUS ADV ALONE IN HBEAG (+) CHRONIC HEPATITIS B: EFFICACY AND MECHANISMS OF TREATMENT RESPONSE (updated 11/03/2004)

§       CONTINUED EFFICACY AND SAFETY OF ADEFOVIR DIPIVOXIL IN CHRONIC HEPATITIS B PATIENTS WITH LAMIVUDINE RESISTANT HBV: 1 YEAR RESULTS (updated 11/03/2004)

Emtricitabine, FTC

§       A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EMTRICITABINE (FTC, EMTRIVA) ADMINISTERED ONCE-DAILY FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION (updated 10/31/2004)

§       CORRELATION BETWEEN BASELINE GENOTYPE AND ANTIVIRAL RESPONSE TO EMTRICITABINE 200 MG QD AMONG HBEAG NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B INFECTION (updated 11/03/2004)

Entecavir

§        ENTECAVIR DEMONSTRATES SUPERIOR HISTOLOGIC AND VIROLOGIC EFFICACY OVER LAMIVUDINE IN NUCLEOSIDE-NAIVE HBEAG(-) CHRONIC HEPATITIS B: RESULTS OF PHASE III TRIAL ETV-027 (updated 11/01/2004)

§        ENTECAVIR IS SUPERIOR TO LAMIVUDINE FOR THE TREATMENT OF HBEAG(+) CHRONIC HEPATITIS B: RESULTS OF PHASE III STUDY ETV-022 IN NUCLEOSIDE-NAďVE PATIENTS  (updated 10/31/2004)

§        ENTECAVIR IS SUPERIOR TO LAMIVUDINE AT REDUCING HBV DNA IN PATIENTS WITH CHRONIC HEPATITIS B REGARDLESS OF BASELINE ALANINE AMINOTRANSFERASE LEVELS (updated 11/03/2004)

§        EMERGENCE OF ENTECAVIR RESISTANT HEPATITIS B VIRUS AFTER ONE YEAR OF THERAPY IN PHASE II & III STUDIES IS ONLY OBSERVED IN LAMIVUDINE REFRACTORY PATIENTS (updated 11/03/2004)

§        HEPATIC IMPAIRMENT DOES NOT ALTER SINGLE-DOSE PHARMACOKINETICS AND SAFETY OF ENTECAVIR (updated 11/03/2004)

§        ENTECAVIR IS SUPERIOR TO CONTINUED LAMIVUDINE FOR THE TREATMENT OF LAMIVUDINE-REFRACTORY, HBeAG(+) CHRONIC HEPATITIS B: RESULTS OF PHASE III STUDY ETV-026 (updated 11/03/2004)

§        ENTECAVIR IS WELL-TOLERATED FOR TREATMENT OF CHRONIC HEPATITIS B: PHASE III SAFETY ANALYSIS IN NUCLEOSIDE-NAďVE AND LAMIVUDINE-REFRACTORY PATIENTS (updated 11/03/2004)

§        A RANDOMIZED, PLACEBO-CONTROLLED STUDY (ETV-056) IN CHINA OF THE EFFICACY AND SAFETY OF ENTECAVIR IN CHRONIC HEPATITIS B PATIENTS WHO HAVE FAILED LAMIVUDINE (updated 11/03/2004)

Clevudine

§       A PHASE II, RANDOMIZED TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF CLEVUDINE FOR 12 WEEKS IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/03/2004)

§       A 12-WEEK CLEVUDINE THERAPY SHOWED DURABLE ANTIVIRAL ACTIVITY AND NORMALIZATION OF ALANINE TRANSMINASE LEVELS FOR 6 MONTHS AFTER DISCONTINUATION OF TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/03/2004)

§       CLEVUDINE THERAPY FOR 24 WEEKS FURTHER REDUCED SERUM HEPATITIS B VIRUS DNA LEVELS AND INCREASED ALT NORMALIZATION RATES WITHOUT EMERGENCE OF VIRAL BREAKTHROUGH THAN 12-WEEK CLEVUDINE THERAPY

§       CLEVUDINE RE-ADMINISTERED TO THE PATIENTS WITH PREVIOUS 12-WEEKS CLEVUDINE EXPERIENCE IS AS ACTIVE AS TO THE NAIVE PATIENTS IN TERMS OF VIROLOGICAL AND BIOCHEMICAL RESPONSES (updated 11/03/2004)

Tenofovir

§       EFFECT OF SWITCHING TO TENOFOVIR WITH EMTRICITABINE OR LAMIVUDINE IN PATIENTS WITH CHRONIC HEPATITIS B FAILING TO RESPOND TO AN ADEFOVIR-CONTAINING REGIMEN (updated 11/03/2004)

Telbivudine

§       CLINICAL PHARMACOKINETICS OF TELBIVUDINE, A POTENT ANTIVIRAL FOR HEPATITIS B, IN SUBJECTS WITH IMPAIRED HEPATIC OR RENAL FUNCTION (updated 11/03/2004)

Other Antivirals

§        PHASE I/II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE NOVEL ANTI-HBV AGENT LB80380/ANA380 IN PATIENTS WITH CHRONIC HBV INFECTION  (updated 11/01/2004)

§        VALTORCITABINE PROVIDES POTENT SUPPRESSION OF HEPATITIS B VIRUS IN PATIENTS WITH CHRONIC HEPATITIS B: RESULTS OF A PHASE I/II CLINICAL TRIAL  (updated 11/01/2004)

§        CORRELATES OF RESPONSE IN PATIENTS WITH CHRONIC HBV INFECTION RECEIVING LIBIVIRUMAB AND EXBIVIRUMAB (HEPEX-B(tm)) (updated 11/03/2004)

§       IN VITRO CHARACTERISATION OF THE ANTI-HBV ACTIVITY AND CROSS-RESISTANCE PROFILE OF 2',3'-DIDEOXY-3'-FLUOROGUANOSINE (updated 11/03/2004)

§       BINDING AND INHIBITION OF HEPATITIS B VIRUS C GENE PROMOTER BY ADENO-ASSOCIATED VIRUS REP78 PROTEIN IN VITRO (updated 11/03/2004)

§       SAFETY, TOLERANCE, PHARMACOKINETICS AND PHARMACODYNAMICS OF REMOFOVIR, A LIVER-TARGETING PRODRUG OF PMEA IN HBV PATIENTS FOLLOWING DAILY DOSING FOR 28 DAYS (updated 11/03/2004)

 

THERAPEUTIC VACCINES

§        INDUCTION OF HBS-SPECIFIC T CELL RESPONSES IN HBV CHRONIC CARRIERS BY AN HEPATITIS B VIRUS DNA VACCINE (updated 11/01/2004)

§        PRODUCTION OF IMMUNOGENIC HBSAG-PULSED HUMAN DENDRITIC CELLS (DCS): EVALUATION OF SAFETY AND EFFICACY OF HBSAG-PULSED DCS IN NORMAL VOLUNTEERS, HB VACCINE NONRESPONDERS AND PATIENTS WITH CHRONIC HEPATITIS B  (updated 11/01/2004)

§        VACCINATION WITH AN EXPERIMENTAL ANTI-HBV VACCINE YIELDS HIGH RESPONSE RATES IN LIVER TRANSPLANT PATIENTS AND ALLOWS SAFE DISCONTINUATION OF HEPATITIS B IMMUNOGLOBULINS PROPHYLAXIS  (updated 11/01/2004)

§        DEVELOPMENT OF A NON-REPLICATIVE, SINGLE-SHOT DNA-BASED VACCINE EXPRESSING ALL HEPATITIS B VIRAL ANTIGENS (updated 11/03/2004)

§        BREAKING IMMUNE TOLERANCE IN CHRONIC HEPATITIS B BY DENDRITIC CELL VACCINATION IN HBV TRIMERA MICE (updated 11/03/2004)

§        SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS OF A PHASE II TRIAL OF THERAPEUTIC VACCINES FOR CHRONIC HBV IN THE GAMBIA (updated 11/03/2004)

 

HBV INTERFERON TREATMENT

§       SUCCESSFUL TREATMENT WITH PEGYLATED INTERFERON IN HBV NON-RESPONDERS TO STANDARD INTERFERON AND LAMIVUDINE (updated 11/03/2004)

§       BETTER SAFETY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS B THAN IN PATIENTS WITH CHRONIC HEPATITIS C WHEN TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS(r)) MONOTHERAPY (updated 11/03/2004)

 

Combination Antiviral and Interferon Treatment

§        PEGINTERFERON ALFA-2A (40KD) (PEGASYS(r)) MONOTHERAPY AND IN COMBINATION WITH LAMIVUDINE IS MORE EFFECTIVE THAN LAMIVUDINE MONOTHERAPY IN HBEAG-POSITIVE CHRONIC HEPATITIS B: RESULTS FROM A LARGE, MULTINATIONAL STUDY (updated 10/31/2004)

§        RANDOMIZED, DOUBLE-BLIND STUDY COMPARING ADEFOVIR DIPIVOXIL (ADV) PLUS EMTRICITABINE (FTC) COMBINATION THERAPY VERSUS ADV ALONE IN HBeAG (+) CHRONIC HEPATITIS B: EFFICACY AND MECHANISMS OF TREATMENT RESPONSE (updated 11/03/2004)

§        PROFOUND ON-TREATMENT VIRAL SUPPRESSION WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS(r)) PLUS LAMIVUDINE COMBINATION THERAPY LIMITS THE DEVELOPMENT OF YMDD MUTATIONS, BUT DOES NOT IMPROVE SUSTAINED RESPONSE RATES OVER PEGINTERFERON ALFA-2A (40KD) ALONE (updated 11/03/2004)

§        ALT FLARES AND SUSTAINED ALT RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS(r)), PEGINTERFERON ALFA-2A (40KD) PLUS LAMIVUDINE OR LAMIVUDINE ALONE (updated 11/03/2004)

§        THE FIRST DETAILED ANALYSIS OF PREDICTORS OF RESPONSE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B: DATA FROM A MULTICENTER, RANDOMIZED, PARTIALLY DOUBLE-BLIND STUDY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS(r)) ALONE OR IN COMBINATION WITH LAMIVUDINE VS LAMIVUDINE ALONE (updated 11/03/2004)

§        HBSAG SEROCONVERSION IN CHRONIC HBV PATIENTS TREATED WITH PEGYLATED INTERFERON ALPHA-2B ALONE OR IN COMBINATION WITH LAMIVUDINE. THE ROLE OF HBV GENOTYPE (updated 11/03/2004)

§        HBV-DNA AND INFECTED HEPATOCYTES DYNAMICS IN HBeG-NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS(r)), LAMIVUDINE, OR PEGASYS(r) PLUS LAMIVUDINE COMBINATION THERAPY USING A NEW BIO-MATHEMATICAL MODEL (updated 11/03/2004)

§        HBV VIRAL DYNAMICS DURING TREATMENT OF NAIVE PATIENTS WITH HBEAG(-) CHRONIC HEPATITIS B WITH PEGYLATED INTERFERON ALPHA 2B ALONE OR IN COMBINATION WITH LAMIVUDINE (updated 11/03/2004)

 

HBV VIRAL RESISTANCE TO DRUGS

§        CHANGES IN THE STABILITY OF HBV-SPECIFIC CTL EPITOPES BY YMDD MUTATIONS MAY DETERMINE THE OCURRENCE OF BREAKTHROUGH HEPATITIS (updated 11/01/2004)

§        HBV MUTANTS ASSOCIATED WITH CLINICAL RESISTANCE TO ADEFOVIR DIPIVOXIL DISPLAY ONLY SMALL DECREASES IN ANTIVIRAL SENSITIVITY IN VITRO (updated 11/01/2004)

§        HEPATITIS B VIRUS RESISTANCE TO ENTECAVIR INVOLVES NOVEL CHANGES IN THE VIRAL POLYMERASE (updated 11/01/2004)

§        IN VITRO CROSS-RESISTANCE TESTING OF ADEFOVIR, LAMIVUDINE, TELBIVUDINE (L-DT), ENTECAVIR AND OTHER ANTI-HBV COMPOUNDS AGAINST FOUR MAJOR MUTATIONAL PATTERNS OF LAMIVUDINE-RESISTANT HBV (updated 11/01/2004)

§        LOW LIVER CELL PROLIFERATION AND HIGH APOPTOSIS RATES IN PATIENTS WITH HBeAG-NEGATIVE CHRONIC HEPATITIS B RESPONDING TO INTERFERON (updated 11/01/2004)

§        MOLECULAR MODELLING OF ENTECAVIR RESISTANT MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE SELECTED DURING THERAPY (updated 11/01/2004)

§        MOLECULAR MODELLING OF HEPATITIS B VIRUS POLYMERASE AND ADEFOVIR RESISTANCE IDENTIFIES THREE CLUSTERS OF MUTATIONS (updated 11/01/2004)

§        VIRAL DYNAMICS FOR LDT (TELBIVUDINE)-TREATED HEPATITIS B PATIENTS: HIGH DEGREE OF INITIAL INHIBITION WITH DOSE-DEPENDENT SECOND-PHASE HBV CLEARANCE SUGGESTS A NEW MODEL FOR HBV DYNAMICS (updated 11/01/2004)

§        PREDICTION OF BREAKTHROUGH HEPATITIS DUE TO LAMIVUDINE-RESISTANT HEPATITIS B VIRUS BY A SENSITIVE S EMI-QUANTITATIVE ASSAY FOR THE MUTANT VIRUS (updated 11/03/2004)

§       DETECTION OF PREDOMINANT YMDD MUTANTS AT THE STAGE OF VIRAL DNA NEGATIVITY FOR THE PROGNOSIS OF VIRAL DNA BREAKTHROUGH (updated 11/03/2004)

§       EARLY VIRAL KINETICS DURING THERAPY WITH LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN PATIENTS WITH LAMIVUDINE RESISTANT CHRONIC HEPATITIS B (updated 11/03/2004)

§       A NOVEL LINE PROBE ASSAY (INNO-LIPA HBV DR V2) FOR DETECTING DRUG RESISTANCE IN HEPATITIS B VIRUS INFECTED PATIENTS DURING LAMIVUDINE AND ADEFOVIR DIPIVOXIL THERAPY (updated 11/03/2004)

 

HBV PREVENTION 

§       EFFICACY AND SAFETY OF LAMIVUDINE IN LATE PREGNANCY FOR THE PREVENTION OF MOTHER-CHILD TRANSMISSION OF HEPATITIS B; A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (updated 11/03/2004)

§       ANTIGEN-PRESENTING DENDRITIC CELLS LOADED WITH HEPATITIS B SURFACE ANTIGEN IS CAPABLE OF INDUCING AND MAINTAINING ANTI-HBS IN IMMUNOSUPPRESSED MOUSE: STRATEGY FOR DEVELOPING PROPHYLACTIC VACCINE AGAINST HEPATITIS B VIRUS IN IMMUNOSUPPRESSED INDIVIDUALS (updated 11/03/2004)

HBV and Liver Transplants

§        HBSAG LEVEL AT TIME OF LIVER TRANSPLANTATION PREDEFINES EARLY HBSAG AND ANTI-HBS KINETICS AND AFFECTS HBV-DNA DECREASE DURING IMMUNOGLOBULIN ADMINISTRATION  (updated 11/01/2004)

§        LAMIVUDINE MONO PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS B-SINGLE CENTER EXPERIENCE OVER 10 YEARS (updated 11/01/2004)

§        LAMIVUDINE PROPHYLAXIS WITH ADEFOVIR SALVAGE IN HEPATITIS B PATIENTS UNDERGOING LIVER TRANSPLANT IS MORE COST EFFECTIVE THAN COMBINATION LAMIVUDINE/HBIG THERAPY  (updated 11/01/2004)

§        LIVER TRANSPLANTATION FOR HEPATITIS B ASSOCIATED END STAGE LIVER DISEASE IN KOREA  (updated 11/01/2004)

§        LIVER TRANSPLANTATION IN LAMIVUDINE-RESISTANT YMDD-MUTANT CARRIERS: ROLE OF ADEFOVIR-DIPIVOXIL IN PREVENTION OF HEPATITIS B VIRUS RECURRENCE  (updated 11/01/2004)

§        LIVING DONOR LIVER TRANSPLANTATION FROM HEPATITIS B CORE ANTIBODY POSITIVE DONORS  (updated 11/01/2004)

§        RELATION BETWEEN HBV GENOTYPES AND HBV VARIANTS AND INDICATIONS FOR LIVER TRANSPLANT (LT) IN HEPATITIS B PATIENTS IN THE U.S.*  (updated 11/01/2004)

§        THE EFFECT OF HEPATITIS B REPLICATION STATUS ON HEPATITIS B IMMUNOGLOBULIN DOSE REQUIREMENTS AND PHARMACOKINETICS IN LIVER TRANSPLANTATION FOR HEPATITIS B VIRUS  (updated 11/01/2004)

§        TREATMENT OF LAMIVUDINE RESISTANCE HEPATITIS B PATIENTS AFTER LIVER TRANSPLANT: RESULTS OF A SINGLE CENTER EXPERIENCE  (updated 11/01/2004)

§        LONG-TERM SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL (ADV) IN THE TREATMENT OF CHRONIC HEPATITIS B IN PATIENTS PRE-AND POST-LIVER TRANSPLANTATION (OLT) WITH LAMIVUDINE-RESISTANT (LAM-R) HEPATITIS B VIRUS (HBV) (updated 11/03/2004)

 

HBV AND LIVER CANCER

§        CHANGE OF HEPATITIS B VIRUS ACTIVITIES WITH TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION THERAPY IN PATIENTS WITH HBV-RELATED HEPATOCELLULAR CARCINOMA  (updated 11/01/2004)

§        HEPATITIS B VIRAL LOAD IS ASSOCIATED WITH THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) (updated 11/01/2004)

§        HEPATITIS B VIRUS-RELATED INSERTIONAL MUTAGENESIS IN PATIENTS WITH CHRONIC HEPATITIS B AS AN EARLY DRASTIC GENETIC CHANGE LEADING TO HEPATOCARCINOGENESIS (updated 11/01/2004)

§        IMPROVED SURVIVAL WITH SCREENING FOR HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B - PRELIMINARY RESULTS OF A NATIONAL SURVEILLANCE PROGRAM (updated 11/01/2004)

 

HBV PREVALENCE AND PUBLIC POLICY

§        OCCULT HEPATITIS B VIRUS INFECTION IN A NORTH AMERICAN ADULT HEMODIALYSIS PATIENT POPULATION (updated 11/01/2004)

§        OCCULT HEPATITIS B VIRUS INFECTION IN A COMMUNITY-BASED POPULATION (updated 11/01/2004)

§        HIGH PREVALENCE OF CHRONIC HEPATITIS B (HBV) INFECTION IN ADULT CHINESE AMERICANS LIVING IN CALIFORNIA (updated 11/03/2004)

§        INPATIENT COSTS OF LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN THE UNITED STATES, 1993-2001 (updated 11/03/2004)

 

HBV GENOTYPES

§        A CASE-CONTROL STUDY FOR DIFFERENCES AMONG HEPATITIS B VIRUS INFECTIONS OF GENOTYPES A (SUBTYPES AA AND AE) AND D (updated 11/01/2004)

§        MBL2 GENOTYPES ARE IMPORTANT DETERMINANTS OF HBV CLEARANCE OR PERSISTENCE (updated 11/01/2004)

§        SUBTYPES OF HBV GENOTYPE A IN THE UNITED STATES - CLINICAL SIGNIFICANCE AND IDENTIFICATION OF A NOVEL SUBTYPE  (updated 11/01/2004)

§        HBSAG SEROCONVERSION IN CHRONIC HBV PATIENTS TREATED WITH PEGYLATED INTERFERON ALPHA-2B ALONE OR IN COMBINATION WITH LAMIVUDINE. THE ROLE OF HBV GENOTYPE (updated 11/03/2004)

§        CLINICAL SIGNIFICANCE OF HEPATITIS B VIRUS DNA LEVELS IN HBEAG-NEGATIVE, HBV GENOTYPE D-INFECTED PATIENTS (updated 11/03/2004)

 

HBeAg-Negative Hepatitis B

§        NATURALLY OCCURRING MUTATIONS IN HEPATITIS B VIRUS CORE GENE MODULATE CORE PROTEIN AND e ANTIGEN EXPRESSION OR THEIR ANTIGENICITY(updated 11/01/2004)

§        PREDICTION OF LONG-TERM PROGNOSIS OF HEPATITIS B VIRUS CARRIERS WITH NEGATIVE HBe ANTIGEN AND NORMAL TRANSAMINASE LEVEL(updated 11/01/2004)

§        SERUM HBV-DNA LEVELS HIGHER THAN 105 CP/ML ARE ASSOCIATED WITH SIGNIFICANT INFLAMMATORY ACTIVITY IN THE LIVER OF HBeAG NEGATIVE HBSAG CARRIERS WITH PERSISTENTLY NORMAL OR ELEVATED ALT (updated 11/01/2004)

§        THE PREVALENCE OF HBV GENOTYPES, VIRAL VARIANTS AND HBeAG-VE CHRONIC HEPATITIS B (E-CHB) IN A CANADIAN CENTER (updated 11/01/2004)

§        ACCUMULATION OF BASIC CORE PROMOTER MUTATIONS DURING THE NATURAL COURSE OF HBV INFECTION (updated 11/03/2004)

§        LONG-TERM OUTCOME OF PATIENTS WITH HBeAG-NEGATIVE CHRONIC HEPATITIS B (CHBe-) UNDER NUCLEOS(T)IDE ANALOGUES MAINTENANCE THERAPY STARTING WITH LAMIVUDINE (LAM) (updated 11/03/2004)

HBV Disease Progression

§        BMI IS AN INDEPENDENT PREDICTOR OF DISEASE PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS B (updated 11/01/2004)

§        VIRAL LOAD AS A PREDICTOR OF LIVER DISEASE IN CHRONIC HEPATITIS B INFECTION (updated 11/01/2004)

§        DYNAMIC RANGE AND REPRODUCIBILITY OF COBAS TAQMAN DETECTION OF HEPATITIS B VIRUS DNA (updated 11/03/2004)

§        HEPATITIS B VIRUS LAMIVUDINE RESISTANT MUTATIONS ABROGATE SECRETION OF HEPATITIS DELTA VIRUS (updated 11/03/2004)

§        INVOLVEMENT OF HEPATITIS B VIRUS (HBV) COVALENTLY CLOSED CIRCULAR DNA IN SUSTAINED HBV REPLICATION IN IMMUNOCOMPROMISED MICE AFTER HYDRODYNAMIC INJECTION OF A NAKED PLASMID ENCODING HBV DNA (updated 11/03/2004)

§        QUANTITATIVE DETECTION OF (-) AND (+) STRAND HBV DNA AND THEIR REPLICATIVE INTERMEDIATES IN THE LIVER OF CHRONICALLY INFECTED PATIENTS (updated 11/03/2004)

§       ACTIVITY OF SYSTEMICALLY ADMINISTERED STABILIZED SIRNAS IN A MOUSE MODEL OF HBV REPLICATION (updated 11/03/2004)

 

HBV, HCV AND HIV COINFECTIONS

§       IMPACT OF HAART ON HEPATITIS B VIRUS CO-INFECTION: ASSOCIATION BETWEEN IMMUNORESTORATION AND HBS/E ANTIGEN SEROCONVERSION (updated 11/03/2004)

§       LONGITUDINAL EVALUATION OF VIROLOGICAL PROFILES IN HBV/HCV COINFECETED PATIENTS, AN ITALIAN MULTICENTRE STUDY (updated 11/03/2004)

§       HEPATITIS B VIRUS (HBV) RESPONSE TO THERAPY WITH LAMIVUDINE (LAM) AND TENOFOVIR (TFV) IN HBV/HIV CO-INFECTED PATIENTS: IMPACT OF GENOTYPE AND TREATMENT REGIMEN (updated 11/03/2004)

§       CHARACTERISTICS OF HEPATITIS B VIRUS (HBV) AND HIV CO-INFECTED PATIENTS IN FRANCE: A PROSPECTIVE MULTICENTER SURVEY (updated 11/03/2004)

§       LONG TERM EFFECTS OF INTERFERON ALPHA THERAPY INTRAVENOUS DRUG USERS WITH TRIPLE INFECTION BY HEPATITIS B, C AND D VIRUS (updated 11/03/2004)

 

HBV AND THE IMMUNE SYSTEM

§        A SHORT SEQUENCE IN THE 3' END OF CORE GENE IS CRITICAL FOR HEPATITIS B VIRUS GENOME REPLICATION, E ANTIGEN PROCESSING, AND CORE PROTEIN NUCLEAR LOCALIZATION  (updated 11/01/2004)

§        ANALYSIS OF INTRAHEPATIC IMMUNE RESPONSE IDENTIFIES FOUR STAGES OF CHRONIC HBV INFECTION (updated 11/01/2004)

§        CHRONIC HBV PATIENTS DISPLAY IMPAIRED MATURATION AND ANTIGEN PRESENTATION OF MYELOID DENDRITIC CELLS AND REDUCED IFN-a PRODUCTION OF PLASMACYTOID DENDRITIC CELLS (updated 11/01/2004)

§        CYTOPATHIC EFFECTS OF HEPATITIS B VIRUS INFECTION IN LONG-TERM INFECTED CHIMERIC UPA-SCID MICE (updated 11/01/2004)

§        EDITING OF HEPATITIS B VIRUS DNA BY THE CYTIDINE DEAMINASE APOBEC3G (updated 11/01/2004)

§        FUNCTIONAL VARIATION IN THE IFNAR2 AND IL10RB GENES LINKED TO PERSISTENT HBV INFECTION (updated 11/01/2004)

§        HBX AND THE CELLULAR ACETYLTRANSFERASE PCAF ARE CO-RECRUITED IN VIVO ONTO THE HBV CCCDNA MINICHROMOSOME TO REGULATE THE COUPLED VIRAL TRANSCRIPTION/REPLICATION PROCESS (updated 11/01/2004)

§        IMPAIRED CAPACITY OF LIVER DENDRITIC CELLS FROM MURINE HEPATITIS B VIRUS (HBV) CARRIER TO INDUCE AND SUSTAIN HBV-SPECIFIC ANTIVIRAL IMMUNITY: RELEVANCE TO HBV PERSISTENCY  (updated 11/01/2004)

§        IMPAIRED TOLL-LIKE RECEPTOR EXPRESSION IN CHRONIC HEPATITIS B: IMPLICATIONS FOR PATHOGENESIS AND THERAPY (updated 11/01/2004)

§        INTERACTION OF HBV VARIANTS DETERMINES THE PHENOTYPE OF A HETEROGENEOUS VIRAL POPULATION (updated 11/01/2004)

§        LOW LIVER CELL PROLIFERATION AND HIGH APOPTOSIS RATES IN PATIENTS WITH HBeAG-NEGATIVE CHRONIC HEPATITIS B RESPONDING TO INTERFERON (updated 11/01/2004)

§        MECHANISMS OF HYPORESPONSIVENESS OF HBV-SPECIFIC CD4+ T CELLS IN CHRONIC HEPATITIS B (updated 11/01/2004)

§        REGULATORY T CELLS CONTRIBUTE TO IMMUNOLOGIC HYPORESPONSIVENESS IN CHRONIC HBV PATIENTS (updated 11/01/2004)

§        SUSCEPTIBILITY TO ANTIVIRALS OF AN HBV STRAIN HARBORING POLYMERASE MUTATIONS CONFERRING RESISTANCE TO BOTH LAMIVUDINE AND ADEFOVIR (updated 11/01/2004)

§        VARIABILITY OF HEPATITIS B VIRUS SURFACE ANTIGEN IN CHRONIC HEPATITIS B VIRUS CARRIERS WHO PRESENT BOTH HBS AG AND ANTI-HBS ANTIBODY (updated 11/01/2004)